Navigation Links
Varian Medical Systems Schedules Fiscal Year End Review for Investors in New York
Date:10/18/2011

PALO ALTO, Calif., Oct. 18, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that its management will hold a fiscal year 2011 review for investors on November 3, 2011 at the Concierge Conference Center, 780 Third Avenue, New York, from 11:30 a.m. ET to 1:00 p.m. ET.

Management will include Tim Guertin, President and CEO; Dow Wilson, Executive Vice President and Chief Operating Officer; Kolleen Kennedy, Senior Vice President and President of Oncology Systems; Robert Kluge, Senior Vice President and President of X-Ray Products; Elisha Finney, Senior Vice President and CFO; Lester Boeh, Vice President Emerging Businesses; and Spencer Sias, Vice President, Investor Relations.

You may RSVP by contacting Anne Rambo at (650) 424-5834, or email: anne.rambo@varian.com.  

The meeting will be webcast and may be accessed via: www.varian.com/investor

Web conferences will be archived on the company website for a year.  Additional information about Varian Medical Systems can be obtained on the company's website.  Investors can subscribe to receive automatic "e-mail alerts" regarding Varian news and events via the company website at www.varian.com/investor.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Spencer Sias, (650) 424-5782
Vice President, Corporate Communications
and Investor Relations
spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets ... (APAC) breast cancer market will experience considerable expansion ... at a Compound Annual Growth Rate (CAGR) of 8.5%. ... - states that the Asia-Pacific ... billion in 2014 to $3.4 billion by 2021, at a ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
(Date:2/11/2016)... F ast access ... at the point of need ... medical information products and services, has launched a ClinicalKey mobile ... a mobile device. Elsevier designed the mobile app to allow users to ... available in Android and iOS formats for mobile ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper published ... , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance of ... rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage in ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for Case ... Board of Commissioners. Individuals interested in volunteer board service are encouraged to apply. ... practice settings and across allied health to contribute to its mission and vision. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing curves. It’s ... older, who gather once a year to play softball to raise money through ... the more than 50 players who competed in this year’s softball tournament share a ...
(Date:2/11/2016)... NY (PRWEB) , ... February 11, 2016 , ... ... enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to include ... in vein illumination with an estimated 85% share of the market, facilitates adherence ...
Breaking Medicine News(10 mins):